Saline Nasal Mist ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 127 | Frontotemporal lobar degeneration | 2 |
127. Frontotemporal lobar degeneration
Clinical trials : 90 / Drugs : 87 - (DrugBank : 30) / Drug target genes : 39 - Drug target pathways : 88
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01937013 (ClinicalTrials.gov) | September 12, 2013 | 3/9/2013 | Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia | Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia | Frontotemporal Dementia | Drug: Intranasal oxytocin;Drug: Saline Nasal Mist | Lawson Health Research Institute | Canadian Institutes of Health Research (CIHR) | Completed | 30 Years | 85 Years | All | 52 | Phase 2 | Canada |
| 2 | NCT01386333 (ClinicalTrials.gov) | June 2011 | 29/6/2011 | Safety Study of Intranasal Oxytocin in Frontotemporal Dementia | A Phase I Dose Finding Study of Intranasal Oxytocin in Frontotemporal Dementia, Protocol # FTDOXY10EF | Frontotemporal Dementia | Drug: oxytocin;Drug: Saline Nasal Mist | Lawson Health Research Institute | The Consortium of Canadian Centres for Clinical Cognitive Research (C5R) | Completed | 30 Years | 80 Years | Both | 23 | Phase 1 | Canada |